Eli Lilly and Company (NYSE:LLY) is Blackhawk Capital Partners LLC.’s 6th Largest Position

Blackhawk Capital Partners LLC. raised its position in Eli Lilly and Company (NYSE:LLY) by 6.9% during the second quarter, HoldingsChannel reports. The firm owned 5,215 shares of the company’s stock after buying an additional 335 shares during the quarter. Eli Lilly and Company accounts for 2.9% of Blackhawk Capital Partners LLC.’s holdings, making the stock its 6th biggest position. Blackhawk Capital Partners LLC.’s holdings in Eli Lilly and Company were worth $4,722,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after acquiring an additional 1,133,810 shares in the last quarter. Capital World Investors lifted its holdings in shares of Eli Lilly and Company by 0.3% in the 4th quarter. Capital World Investors now owns 26,949,773 shares of the company’s stock valued at $15,709,466,000 after purchasing an additional 89,720 shares during the last quarter. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $5,992,890,000. Capital Research Global Investors grew its stake in Eli Lilly and Company by 6.0% during the 1st quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after buying an additional 453,939 shares during the last quarter. Finally, Capital International Investors increased its position in Eli Lilly and Company by 5.1% during the first quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock worth $5,424,243,000 after buying an additional 335,560 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on LLY shares. Jefferies Financial Group increased their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Guggenheim raised their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Argus lifted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Finally, Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and boosted their price target for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $19.82 during mid-day trading on Friday, hitting $960.02. 2,456,992 shares of the company were exchanged, compared to its average volume of 3,070,253. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The company has a market capitalization of $912.41 billion, a P/E ratio of 141.39, a PEG ratio of 1.81 and a beta of 0.41. The business’s 50 day simple moving average is $891.13 and its two-hundred day simple moving average is $819.99. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.54%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 192,794 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the sale, the insider now owns 98,208,810 shares in the company, valued at $81,490,724,273.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 192,794 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $829.77, for a total transaction of $159,974,677.38. Following the transaction, the insider now directly owns 98,208,810 shares in the company, valued at approximately $81,490,724,273.70. The disclosure for this sale can be found here. Insiders sold a total of 1,097,883 shares of company stock valued at $972,022,568 over the last 90 days. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.